Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.44 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL298650 | 0.91 | BRAF (0.51) | BRAFSLC40A1CYP3A4NAMPTKIT | |
| SCHEMBL298074 | 0.91 | CLK1 (0.46) | BRAFCYP2C9CYP3A4 | |
| SCHEMBL298469 | 0.90 | ALDH1A1 (0.47) | BRAFGPR27CYP3A4NAMPTKIT | |
| SCHEMBL299744 | 0.88 | CCR9 (0.51) | BRAFCYP3A4 | |
| SCHEMBL299148 | 0.86 | BRAF (0.49) | BRAFCYP2C19CYP2C9BACE1CYP3A4 | |
| SCHEMBL298675 | 0.86 | BRAF (0.49) | BRAFSLC40A1NAMPT | |
| SCHEMBL298860 | 0.85 | CYP3A4 (0.54) | BRAFCYP2C19CYP2C9CYP3A4KIT | |
| SCHEMBL298904 | 0.84 | CYP3A4 (0.47) | BRAFCYP2C9SLC40A1CYP3A4KIT | |
| SCHEMBL298424 | 0.83 | SLC40A1 (0.48) | BRAFCYP2C9SLC40A1CYP3A4NAMPT | |
| SCHEMBL298731 | 0.83 | BRAF (0.70) | BRAFCYP2C19CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| EP-2427433-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | Plexxikon, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | BRAF 1/4885CYP2C19 2730/4885CYP2C9 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.